European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. DPZ
6. PLTR
7. MSFT
8. NAVN
9. DFTX
10. CNC

Go back to European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV

Jefferies Remains Sidelined on Gilead Sciences (GILD) Following 2Q - PT to $93

July 26, 2016 9:15 AM EDT

Jefferies maintained a Hold rating on Gilead Sciences (NASDAQ: GILD), and cut the price target to $93.00 (from $97.00) following the company's 2Q earnings report. GILD's strong bottom-line results were driven by HIVB strength, as well as buybacks. HIV sales remain strong, with particular... More

Gilead (GILD) Receives Updated CHMP Recommendations on Zydelig as CLL, Follicular Lymphoma Treatment

July 22, 2016 7:19 AM EDT

The CHMP (EMAs Committee for Medicinal Products for Human Use) has confirmed that the benefits of Gilead's (Nasdaq: GILD) Zydelig (idelalisib) in the treatment of the blood cancers chronic lymphocytic leukaemia (CLL) and follicular lymphoma outweigh the risk of side effects. However, following a review it has updated recommendations to minimise the risk of serious infections in patients treated with the medicine.

All patients treated with Zydelig should be given... More